

# Tomas Ganz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3750757/publications.pdf>

Version: 2024-02-01

393  
papers

64,094  
citations

616

124  
h-index

851

244  
g-index

405  
all docs

405  
docs citations

405  
times ranked

35647  
citing authors

#	ARTICLE	IF	CITATIONS
1	Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice. <i>Blood</i> , 2022, 139, 439-451.	1.4	18
2	Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin. <i>Kidney International</i> , 2022, 101, 711-719.	5.2	8
3	Palladium Nanoplate-Based IL-6 Receptor Antagonists Ameliorate Cancer-Related Anemia and Simultaneously Inhibit Cancer Progression. <i>Nano Letters</i> , 2022, 22, 751-760.	9.1	5
4	Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2022, 197, .	2.5	8
5	Human defensin-inspired discovery of peptidomimetic antibiotics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2117283119.	7.1	16
6	Hepcidin: looking back at two decades of progress. , 2022, 1, 191-193.		1
7	Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease. <i>Scientific Reports</i> , 2022, 12, 6695.	3.3	1
8	Hepcidin and Erythroferrone Complement the Athlete Biological Passport in the Detection of Autologous Blood Transfusion. <i>Medicine and Science in Sports and Exercise</i> , 2022, 54, 1604-1616.	0.4	13
9	Ferric pyrophosphate citrate for parenteral administration of maintenance iron: structure, mechanism of action, clinical efficacy and safety. <i>Current Medical Research and Opinion</i> , 2022, 38, 1417-1429.	1.9	2
10	Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 943-949.	2.9	2
11	Isolation and thermal stabilization of mouse ferroportin. <i>FEBS Open Bio</i> , 2021, 11, 26-34.	2.3	1
12	Parenteral iron therapy and phosphorus homeostasis: A review. <i>American Journal of Hematology</i> , 2021, 96, 606-616.	4.1	16
13	Pursuing Orally Bioavailable Hepcidin Analogues via Cyclic N-Methylated Mini-Hepcidins. <i>Biomedicines</i> , 2021, 9, 164.	3.2	4
14	Increase of plasma erythroferrone levels during high-altitude exposure: A sub-analysis of the <sc>TOP OF HOME</sc> study. <i>American Journal of Hematology</i> , 2021, 96, E179-E181.	4.1	8
15	The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a $\beta^2$ -thalassemia mouse model. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	39
16	Serum Erythroferrone During Pregnancy Is Related to Erythropoietin but Does Not Predict the Risk of Anemia. <i>Journal of Nutrition</i> , 2021, 151, 1824-1833.	2.9	12
17	Detection of a Small-Volume Autologous Blood Transfusion by Hepcidin, Erythroferrone, and the Athlete Biological Passport. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
18	Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021, 321, R152-R161.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2021, 99, 1280-1295.	5.2	103
20	Iron-dependent apoptosis causes embryotoxicity in inflamed and obese pregnancy. <i>Nature Communications</i> , 2021, 12, 4026.	12.8	12
21	Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6493.	4.1	205
22	Umbilical Cord Erythroferrone Is Inversely Associated with Hepcidin, but Does Not Capture the Most Variability in Iron Status of Neonates Born to Teens Carrying Singletons and Women Carrying Multiples. <i>Journal of Nutrition</i> , 2021, 151, 2590-2600.	2.9	12
23	AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. <i>Gastroenterology</i> , 2021, 161, 362-365.	1.3	3
24	Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone. <i>Kidney International</i> , 2021, 100, 79-89.	5.2	23
25	New regulators of systemic iron homeostasis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 280.	17.1	4
26	Iron loading induces cholesterol synthesis and sensitizes endothelial cells to TNF $\alpha$ -mediated apoptosis. <i>Journal of Biological Chemistry</i> , 2021, 297, 101156.	3.4	14
27	Erythroferrone structure, function, and physiology: Iron homeostasis and beyond. <i>Journal of Cellular Physiology</i> , 2021, 236, 4888-4901.	4.1	53
28	Glutathione peroxidase 4 and vitamin E control reticulocyte maturation, stress erythropoiesis and iron homeostasis. <i>Haematologica</i> , 2020, 105, 937-950.	3.5	42
29	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. <i>Blood Advances</i> , 2020, 4, 4282-4291.	5.2	77
30	The Authors Reply. <i>Kidney International Reports</i> , 2020, 5, 1119-1120.	0.8	0
31	Iron overload causes a mild and transient increase in acute lung injury. <i>Physiological Reports</i> , 2020, 8, e14470.	1.7	6
32	Anemia of Inflammation in Patients with Intestinal Failure on Home Parenteral Nutrition. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1505-1513.	0.6	3
33	Expression of Iron-Regulatory Hormone Hepcidin and Iron Transporters Ferroportin and ZIP8 in Patients With and Without Chronic Rhinosinusitis. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 1270-1273.	1.9	1
34	Prognostic associations of plasma hepcidin in women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 927-935.	2.5	5
35	Maternal hepcidin determines embryo iron homeostasis in mice. <i>Blood</i> , 2020, 136, 2206-2216.	1.4	37
36	Clinical Immunoassay for Human Hepcidin Predicts Iron Deficiency in First-Time Blood Donors. <i>Journal of applied laboratory medicine</i> , The, 2020, 5, 943-953.	1.3	7

#	ARTICLE	IF	CITATIONS
37	Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk. <i>Kidney Medicine</i> , 2020, 2, 341-353.	2.0	24
38	Drugging erythroferrone to treat anemias. <i>Blood</i> , 2020, 135, 516-518.	1.4	3
39	Fetal and amniotic fluid iron homeostasis in healthy and complicated murine, macaque, and human pregnancy. <i>JCI Insight</i> , 2020, 5, .	5.0	24
40	The role of hepcidin in fetal iron homeostasis. <i>Blood</i> , 2020, 136, 1474-1475.	1.4	3
41	Erythropoietic regulators of iron metabolism. <i>Free Radical Biology and Medicine</i> , 2019, 133, 69-74.	2.9	106
42	Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2057-2065.	0.7	73
43	A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	55
44	The Discovery of the Iron-Regulatory Hormone Hepcidin. <i>Clinical Chemistry</i> , 2019, 65, 1330-1331.	3.2	15
45	Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 272-291.	1.4	45
46	Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD. <i>Kidney International Reports</i> , 2019, 4, 1748-1751.	0.8	6
47	Anemia of Inflammation. <i>New England Journal of Medicine</i> , 2019, 381, 1148-1157.	27.0	323
48	Mechanism of Action and Clinical Attributes of Auryxia® (Ferric Citrate). <i>Drugs</i> , 2019, 79, 957-968.	10.9	24
49	Iron Metabolism in Chronic Kidney Disease Patients. <i>Contributions To Nephrology</i> , 2019, 198, 103-111.	1.1	9
50	Increased gene copy number of <i>DEFA1/DEFA3</i> worsens sepsis by inducing endothelial pyroptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3161-3170.	7.1	41
51	New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and $\beta^2$ -thalassemia. <i>Haematologica</i> , 2019, 104, 1768-1781.	3.5	24
52	William Ganz and His Legacy. <i>Annals of Internal Medicine</i> , 2019, 170, 734.	3.9	0
53	Iron homeostasis in pregnancy and spontaneous abortion. <i>American Journal of Hematology</i> , 2019, 94, 184-188.	4.1	33
54	Anemia of inflammation. <i>Blood</i> , 2019, 133, 40-50.	1.4	609

#	ARTICLE	IF	CITATIONS
55	Effects of maternal iron status on placental and fetal iron homeostasis. Journal of Clinical Investigation, 2019, 130, 625-640.	8.2	119
56	The Aftermath of Surviving Acute Radiation Hematopoietic Syndrome and its Mitigation. Radiation Research, 2019, 191, 323.	1.5	17
57	A Novel Sandwich ELISA to Quantify Erythroferrone in Mouse Serum. Blood, 2019, 134, 2237-2237.	1.4	1
58	Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica, 2018, 103, e141-e142.	3.5	38
59	Evaluation of serum markers for improved detection of autologous blood transfusions. Haematologica, 2018, 103, e443-e445.	3.5	4
60	Iron storage disease (hemochromatosis) and hepcidin response to iron load in two species of pteropodid fruit bats relative to the common vampire bat. Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology, 2018, 188, 683-694.	1.5	13
61	Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatology International, 2018, 12, 83-86.	4.2	41
62	Erythroferrone: An Erythroid Regulator of Hepcidin and Iron Metabolism. HemaSphere, 2018, 2, e35.	2.7	60
63	Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?. American Journal of Nephrology, 2018, 47, 72-83.	3.1	65
64	Comment on “Serum Hepcidin and Soluble Transferrin Receptor in the Assessment of Iron Metabolism in Children on a Vegetarian Diet”. Biological Trace Element Research, 2018, 185, 252-254.	3.5	1
65	Fetal presentation of congenital dyserythropoietic anemia type 1 with novel compound heterozygous CDAN1 mutations. Blood Cells, Molecules, and Diseases, 2018, 71, 63-66.	1.4	8
66	Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood, 2018, 131, 899-910.	1.4	230
67	Iron and infection. International Journal of Hematology, 2018, 107, 7-15.	1.6	214
68	Erythrocytes and erythroblasts give up iron. Blood, 2018, 132, 2004-2005.	1.4	7
69	Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice. Physiological Reports, 2018, 6, e13890.	1.7	23
70	Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E1185-E1193.	3.5	24
71	Erythropoietin and iron “a conflicted alliance?”. Kidney International, 2018, 94, 851-853.	5.2	6
72	Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia, 2018, 32, 2105-2116.	7.2	84

#	ARTICLE	IF	CITATIONS
73	Hepcidin Protects against Lethal Escherichia coli Sepsis in Mice Inoculated with Isolates from Septic Patients. Infection and Immunity, 2018, 86, .	2.2	46
74	Calcium is an essential cofactor for metal efflux by the ferroportin transporter family. Nature Communications, 2018, 9, 3075.	12.8	47
75	Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model. Haematologica, 2017, 102, e85-e88.	3.5	17
76	Erythroferrone and matriptase independently regulate hepcidin expression. American Journal of Hematology, 2017, 92, E61-E63.	4.1	25
77	Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood, 2017, 130, 245-257.	1.4	105
78	Iron homeostasis: An anthropocentric perspective. Journal of Biological Chemistry, 2017, 292, 12727-12734.	3.4	153
79	Does Pathological Iron Overload Impair the Function of Human Lungs?. EBioMedicine, 2017, 20, 13-14.	6.1	6
80	In a Mouse Model of Sepsis, Hepcidin Ablation Ameliorates Anemia More Effectively than Iron and Erythropoietin Treatment. Shock, 2017, 48, 490-497.	2.1	17
81	Mice lacking liver-specific $\beta$ -catenin develop steatohepatitis and fibrosis after iron overload. Journal of Hepatology, 2017, 67, 360-369.	3.7	33
82	Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia. Haematologica, 2017, 102, 60-68.	3.5	29
83	Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica, 2017, 102, e427-e430.	3.5	93
84	Iron-related markers are associated with infection after liver transplantation. Liver Transplantation, 2017, 23, 1541-1552.	2.4	10
85	Hamp1 mRNA and plasma hepcidin levels are influenced by sex and strain but do not predict tissue iron levels in inbred mice. American Journal of Physiology - Renal Physiology, 2017, 313, G511-G523.	3.4	8
86	CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica, 2017, 102, e452-e455.	3.5	22
87	NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges. Nature Reviews Drug Discovery, 2017, 16, 663-664.	46.4	2
88	Macrophages and Iron Metabolism. , 2017, , 803-812.		0
89	Immunoassay for human serum erythroferrone. Blood, 2017, 130, 1243-1246.	1.4	104
90	Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia. JCI Insight, 2017, 2, e92002.	5.0	67

#	ARTICLE	IF	CITATIONS
91	Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F1369-F1377.	2.7	54
92	Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2016, 36, 87-93.	1.6	124
93	Macrophages and Iron Metabolism. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	51
94	Minihhepcidin peptides as disease modifiers in mice affected by $\beta^2$ -thalassemia and polycythemia vera. <i>Blood</i> , 2016, 128, 265-276.	1.4	123
95	Isocitrate treatment of acute anemia of inflammation in a mouse model. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 56, 31-36.	1.4	10
96	Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 727-748.	4.1	111
97	Erythroferrone Regulates Hepcidin Expression Independently of Matriptase 2. <i>Blood</i> , 2016, 128, 3616-3616.	1.4	1
98	Hepcidin. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2016, 57, 1913-1917.	0.5	9
99	Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of $\beta^2$ -thalassemia. <i>Blood</i> , 2015, 126, 2031-2037.	1.4	245
100	Thiol-derivatized minihhepcidins retain biological activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 763-766.	2.2	26
101	Hepcidin-Induced Hypoferremia Is a Critical Host Defense Mechanism against the Siderophilic Bacterium <i>Vibrio vulnificus</i> . <i>Cell Host and Microbe</i> , 2015, 17, 47-57.	11.0	194
102	A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis. <i>Haematologica</i> , 2015, 100, 167-177.	3.5	28
103	Iron homeostasis in host defence and inflammation. <i>Nature Reviews Immunology</i> , 2015, 15, 500-510.	22.7	593
104	Evidence that the expression of transferrin receptor 1 on erythroid marrow cells mediates hepcidin suppression in the liver. <i>Experimental Hematology</i> , 2015, 43, 469-478.e6.	0.4	25
105	Small cyclic agonists of iron regulatory hormone hepcidin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4961-4969.	2.2	35
106	Ironing out Ferroportin. <i>Cell Metabolism</i> , 2015, 22, 777-787.	16.2	474
107	Hepcidin and the Global Burden of Iron Deficiency. <i>Clinical Chemistry</i> , 2015, 61, 577-578.	3.2	20
108	The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. <i>Haematologica</i> , 2015, 100, 124-132.	3.5	173

#	ARTICLE	IF	CITATIONS
109	Hepcidin and Host Defense against Infectious Diseases. PLoS Pathogens, 2015, 11, e1004998.	4.7	163
110	Ferroportin-mediated cellular iron efflux requires extracellular calcium. FASEB Journal, 2015, 29, 566.15.	0.5	0
111	Mice Lacking $\beta$ -catenin In Liver Develop Hepatic Fibrosis In Response To Iron Overload. FASEB Journal, 2015, 29, 611.6.	0.5	0
112	Mouse Models of Anemia of Cancer. PLoS ONE, 2014, 9, e93283.	2.5	21
113	Functional properties of human ferroportin, a cellular iron exporter reactive also with cobalt and zinc. American Journal of Physiology - Cell Physiology, 2014, 306, C450-C459.	4.6	101
114	A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood, 2014, 123, 1129-1136.	1.4	119
115	Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cellular Signalling, 2014, 26, 2539-2550.	3.6	108
116	Hepcidin Induction by Pathogens and Pathogen-Derived Molecules Is Strongly Dependent on Interleukin-6. Infection and Immunity, 2014, 82, 745-752.	2.2	99
117	Testosterone perturbs systemic iron balance through activation of epidermal growth factor receptor signaling in the liver and repression of hepcidin. Hepatology, 2014, 59, 683-694.	7.3	99
118	Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature Genetics, 2014, 46, 678-684.	21.4	890
119	Anemia of Inflammation. Hematology/Oncology Clinics of North America, 2014, 28, 671-681.	2.2	321
120	Erythroferrone contributes to recovery from anemia of inflammation. Blood, 2014, 124, 2569-2574.	1.4	132
121	Use of Minihepcidins As a "Medical Phlebotomy" in the Treatment of Polycythemia Vera. Blood, 2014, 124, 3231-3231.	1.4	1
122	Concurrent Treatment with Minhepcidin and Deferiprone Improves Anemia and Enhances Reduction of Spleen Iron in a Mouse Model of Non-Transfusion Dependent Thalassemia. Blood, 2014, 124, 748-748.	1.4	6
123	Testing the Iron Hypothesis in a Mouse Model of Atherosclerosis. Cell Reports, 2013, 5, 1436-1442.	6.4	44
124	Systemic Iron Homeostasis. Physiological Reviews, 2013, 93, 1721-1741.	28.8	854
125	Design, synthesis, and characterization of cyclic analogues of the iron regulatory peptide hormone hepcidin. Biopolymers, 2013, 100, 519-526.	2.4	12
126	High-Throughput Screening of Small Molecules Identifies Hepcidin Antagonists. Molecular Pharmacology, 2013, 83, 681-690.	2.3	67



#	ARTICLE	IF	CITATIONS
127	Investigation of the role of interleukin-6 and hepcidin antimicrobial peptide in the development of anemia with age. Haematologica, 2013, 98, 1633-1640.	3.5	25
128	Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy. Haematologica, 2013, 98, 1324-1330.	3.5	21
129	Preface: Iron and Cancer. Critical Reviews in Oncogenesis, 2013, 18, preceding 391.	0.4	0
130	The Erythroid Factor Erythroferrone and Its Role In Iron Homeostasis. Blood, 2013, 122, 4-4.	1.4	11
131	Treatment With Minihepcidin Peptide Improves Anemia and Iron Overload In a Mouse Model Of Thalassemia Intermedia. Blood, 2013, 122, 431-431.	1.4	9
132	Cellular Catabolism of the Iron-Regulatory Peptide Hormone Hepcidin. PLoS ONE, 2013, 8, e58934.	2.5	45
133	Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood, 2012, 120, 3829-3836.	1.4	184
134	Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood, 2012, 120, 431-439.	1.4	169
135	Molecular Regulation of Systemic Iron Metabolism. , 2012, , 173-190.		2
136	Macrophages and Systemic Iron Homeostasis. Journal of Innate Immunity, 2012, 4, 446-453.	3.8	212
137	Hepcidin and iron homeostasis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 1434-1443.	4.1	947
138	Molecular Mechanism of Hepcidin-Mediated Ferroportin Internalization Requires Ferroportin Lysines, Not Tyrosines or JAK-STAT. Cell Metabolism, 2012, 15, 905-917.	16.2	124
139	Hepcidin-Induced Endocytosis of Ferroportin Is Dependent on Ferroportin Ubiquitination. Cell Metabolism, 2012, 15, 918-924.	16.2	261
140	Hepcidin Expression in Iron Overload Diseases Is Variably Modulated by Circulating Factors. PLoS ONE, 2012, 7, e36425.	2.5	22
141	IOD IN RHINOS—IMMUNITY GROUP REPORT: REPORT FROM THE IMMUNITY, GENETICS AND TOXICOLOGY WORKING GROUP OF THE INTERNATIONAL WORKSHOP ON IRON OVERLOAD DISORDER IN BROWSING RHINOCEROS (FEBRUARY 2011). Journal of Zoo and Wildlife Medicine, 2012, 43, S117-S119.	0.6	4
142	Iron Metabolism: Interactions with Normal and Disordered Erythropoiesis. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a011668-a011668.	6.2	105
143	IRON HOMEOSTASIS AND ITS DISORDERS IN MICE AND MEN: POTENTIAL LESSONS FOR RHINOS. Journal of Zoo and Wildlife Medicine, 2012, 43, S19-S26.	0.6	13
144	Inhibition of hepcidin transcription by growth factors. Hepatology, 2012, 56, 291-299.	7.3	88

#	ARTICLE	IF	CITATIONS
145	Hepcidin and Disorders of Iron Metabolism. Annual Review of Medicine, 2011, 62, 347-360.	12.2	404
146	The Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders. Hematology American Society of Hematology Education Program, 2011, 2011, 538-542.	2.5	120
147	Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica, 2011, 96, 1099-1105.	3.5	75
148	Hepcidin and iron regulation, 10 years later. Blood, 2011, 117, 4425-4433.	1.4	770
149	Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood, 2011, 117, 2953-2959.	1.4	128
150	Chuvash polycythemia VHRL200W mutation is associated with down-regulation of hepcidin expression. Blood, 2011, 118, 5278-5282.	1.4	41
151	The heterozygote advantage of the Chuvash polycythemia VHRL200W mutation may be protection against anemia. Haematologica, 2011, 96, 1371-1374.	3.5	16
152	Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. British Journal of Haematology, 2011, 153, 118-120.	2.5	32
153	Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver International, 2011, 31, 994-1000.	3.9	24
154	Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology, 2011, 53, 1333-1341.	7.3	203
155	Understanding the Structure/Activity Relationships of the Iron Regulatory Peptide Hepcidin. Chemistry and Biology, 2011, 18, 336-343.	6.0	50
156	A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica, 2011, 96, 500-506.	3.5	70
157	Minihhepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. Journal of Clinical Investigation, 2011, 121, 4880-4888.	8.2	198
158	THE METABOLIC FATE OF THE PEPTIDE HORMONE HEPCIDIN. FASEB Journal, 2011, 25, 1119.3.	0.5	0
159	Mini-Hepcidins Prevent Iron Overload In A Mouse Model of Hereditary Hemochromatosis. Blood, 2011, 118, 689-689.	1.4	0
160	Hepcidin in Male Double Red Blood Cell Donors - Relationship Between Parameters of Iron Metabolism and Erythropoiesis. Blood, 2011, 118, 2109-2109.	1.4	0
161	Proinflammatory state, hepcidin, and anemia in older persons. Blood, 2010, 115, 3810-3816.	1.4	191
162	In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood, 2010, 116, 3635-3644.	1.4	120

#	ARTICLE	IF	CITATIONS
163	Increased Genomic Copy Number of <i>DEFA1/DEFA3</i> Is Associated with Susceptibility to Severe Sepsis in Chinese Han Population. <i>Anesthesiology</i> , 2010, 112, 1428-1434.	2.5	41
164	Neutrophil $\alpha$ -Defensins Cause Lung Injury by Disrupting the Capillary Epithelial Barrier. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 935-946.	5.6	73
165	Hepcidin: an emerging biomarker for iron disorders, inflammatory diseases, and infections. <i>Proceedings of SPIE</i> , 2010, , .	0.8	1
166	$\alpha$ 1-Acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with <i>Schistosoma haematobium</i> . <i>American Journal of Clinical Nutrition</i> , 2010, 91, 1784-1790.	4.7	35
167	Reduction of Serum Hepcidin by Hemodialysis in Pediatric and Adult Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1010-1014.	4.5	86
168	Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced Erythrocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4743-4747.	3.6	197
169	Detection, evaluation, and management of iron-restricted erythropoiesis. <i>Blood</i> , 2010, 116, 4754-4761.	1.4	350
170	Hepcidin Independent Anemia of Inflammation. <i>Blood</i> , 2010, 116, 2050-2050.	1.4	1
171	Minihepcidins: Small Peptides Involved in Disulfide Exchange with Ferroportin Act as Agonists. <i>FASEB Journal</i> , 2010, 24, 1011.1.	0.5	2
172	Hepcidin independent anemia of inflammation. <i>FASEB Journal</i> , 2010, 24, 1011.5.	0.5	0
173	Growth factors EGF and HGF suppress hepcidin by direct interference with bone morphogenetic protein signaling. <i>FASEB Journal</i> , 2010, 24, 1011.4.	0.5	1
174	Iron Deficiency without Anemia In Premenopausal Blood Donors Is Associated with Future Deferral From Whole Blood Donation.. <i>Blood</i> , 2010, 116, 1110-1110.	1.4	0
175	Two Mouse Models Illustrate Different Mechanisms of Anemia of Cancer. <i>Blood</i> , 2010, 116, 2034-2034.	1.4	0
176	Is Serum Hepcidin a Useful Diagnostic Test for Iron Deficiency?. <i>Blood</i> , 2010, 116, 2056-2056.	1.4	0
177	Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response. <i>American Journal of Hematology</i> , 2009, 84, 524-526.	4.1	18
178	Daily regulation of serum and urinary hepcidin is not influenced by submaximal cycling exercise in humans with normal iron metabolism. <i>European Journal of Applied Physiology</i> , 2009, 106, 435-443.	2.5	31
179	Iron in innate immunity: starve the invaders. <i>Current Opinion in Immunology</i> , 2009, 21, 63-67.	5.5	244
180	Differential Processing of $\alpha$ - and $\beta$ -Defensin Precursors by Matrix Metalloproteinase-7 (MMP-7). <i>Journal of Biological Chemistry</i> , 2009, 284, 8301-8311.	3.4	49

#	ARTICLE	IF	CITATIONS
181	Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. Journal of Hepatology, 2009, 50, 1219-1225.	3.7	79
182	Reduced serum hepcidin levels in patients with chronic hepatitis C. Journal of Hepatology, 2009, 51, 845-852.	3.7	148
183	Hepcidin—A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1051-1056.	4.5	279
184	The Role of Hepcidin in Iron Metabolism. Acta Haematologica, 2009, 122, 78-86.	1.4	477
185	Iron Sequestration and Anemia of Inflammation. Seminars in Hematology, 2009, 46, 387-393.	3.4	283
186	Animal Models of Anemia of Inflammation. Seminars in Hematology, 2009, 46, 351-357.	3.4	39
187	Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica, 2009, 94, 1748-1752.	3.5	161
188	The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood, 2009, 114, 437-443.	1.4	149
189	Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood, 2009, 114, 181-186.	1.4	311
190	Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation. Blood, 2009, 114, 493-494.	1.4	68
191	The Role of Hepcidin in Iron Homeostasis. , 2009, , 51-64.		2
192	The determinants of hepcidin—ferroportin interaction. FASEB Journal, 2009, 23, 974.4.	0.5	0
193	Hepatocyte growth factor (HGF) suppresses hepcidin expression in hepatocytes by interfering with BMP—mediated hepcidin induction. FASEB Journal, 2009, 23, 974.2.	0.5	0
194	Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma.. Blood, 2009, 114, 2001-2001.	1.4	0
195	Co-Regulation and Interdependence of the Mammalian Epidermal Permeability and Antimicrobial Barriers. Journal of Investigative Dermatology, 2008, 128, 917-925.	0.7	199
196	Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. British Journal of Haematology, 2008, 142, 669-671.	2.5	29
197	Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. Journal of Hepatology, 2008, 49, 123-133.	3.7	92
198	Functional analysis of the host defense peptide Human Beta Defensin-1: New insight into its potential role in cancer. Molecular Immunology, 2008, 45, 839-848.	2.2	87

#	ARTICLE	IF	CITATIONS
199	Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNR site. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 122-131.	1.4	91
200	Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 132-138.	1.4	206
201	Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 347-352.	1.4	54
202	Iron Homeostasis: Fitting the Puzzle Pieces Together. <i>Cell Metabolism</i> , 2008, 7, 288-290.	16.2	107
203	Involvement of Hepcidin in the Anemia of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2008, 14, 3262-3267.	7.0	99
204	Immunoassay for human serum hepcidin. <i>Blood</i> , 2008, 112, 4292-4297.	1.4	605
205	Structural Aspects of Hepcidin-Ferroportin Binding. <i>Blood</i> , 2008, 112, 119-119.	1.4	4
206	Results of the First International Round Robin for the Quantification of Urinary and Plasma Hepcidin: Need for Standardization. <i>Blood</i> , 2008, 112, 120-120.	1.4	7
207	Immunoassay for Human Hepcidin in Blood. <i>Blood</i> , 2008, 112, 3839-3839.	1.4	1
208	Hepcidin-regulated and hepcidin-independent iron release pathways in hepatocytes and macrophages. <i>FASEB Journal</i> , 2008, 22, 1191.6.	0.5	0
209	Ferroportin residue C326 is critical for its interaction with hepcidin. <i>FASEB Journal</i> , 2008, 22, 1191.4.	0.5	0
210	Ectopic Hepcidin Production in Anemia of Cancer. <i>FASEB Journal</i> , 2008, 22, 1191.12.	0.5	0
211	The Effect of IL-6 in the Anemia of Inflammation. <i>FASEB Journal</i> , 2008, 22, 1191.11.	0.5	0
212	The Role of Hepcidin in Anemia of Cancer. <i>Blood</i> , 2008, 112, 3835-3835.	1.4	2
213	Hepcidin Suppression Relative to Iron Status in Patients with Chronic Hepatitis C.. <i>Blood</i> , 2008, 112, 1860-1860.	1.4	0
214	Molecular Control of Iron Transport. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 394-400.	6.1	293
215	The Molecular Mechanism of Hepcidin-mediated Ferroportin Down-Regulation. <i>Molecular Biology of the Cell</i> , 2007, 18, 2569-2578.	2.1	393
216	Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. <i>Haematologica</i> , 2007, 92, 1407-1410.	3.5	41

#	ARTICLE	IF	CITATIONS
217	Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood, 2007, 110, 2182-2189.	1.4	235
218	Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood, 2007, 110, 4096-4100.	1.4	139
219	Liver iron concentrations and urinary hepcidin in $\alpha$ -thalassemia. Haematologica, 2007, 92, 583-588.	3.5	339
220	Iron and aging. , 2007, , 171-180.		0
221	Urinary hepcidin in congenital chronic anemias. Pediatric Blood and Cancer, 2007, 48, 57-63.	1.5	157
222	High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nature Medicine, 2007, 13, 1096-1101.	30.7	743
223	Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. Journal of Clinical Investigation, 2007, 117, 3339-3349.	8.2	193
224	IL-6 and Anemia of Inflammation.. Blood, 2007, 110, 144-144.	1.4	5
225	Regulation of Iron Metabolism by Hepcidin. Annual Review of Nutrition, 2006, 26, 323-342.	10.1	653
226	Copy number polymorphisms are not a common feature of innate immune genes. Genomics, 2006, 88, 122-126.	2.9	25
227	The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood, 2006, 107, 328-333.	1.4	238
228	DMT1 mutation: response of anemia to darbepoetin administration and implications for iron homeostasis. Blood, 2006, 108, 404-405.	1.4	20
229	Suppression of hepcidin during anemia requires erythropoietic activity. Blood, 2006, 108, 3730-3735.	1.4	439
230	Molecular pathogenesis of anemia of chronic disease. Pediatric Blood and Cancer, 2006, 46, 554-557.	1.5	92
231	Regulation of iron acquisition and iron distribution in mammals. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 690-699.	4.1	189
232	Reversible Deficiency of Antimicrobial Polypeptides in Bacterial Vaginosis. Infection and Immunity, 2006, 74, 5693-5702.	2.2	123
233	Hepcidin and Its Role in Regulating Systemic Iron Metabolism. Hematology American Society of Hematology Education Program, 2006, 2006, 29-35.	2.5	169
234	Macrophages Acquire Neutrophil Granules for Antimicrobial Activity against Intracellular Pathogens. Journal of Immunology, 2006, 177, 1864-1871.	0.8	209

#	ARTICLE	IF	CITATIONS
235	Iron imports. IV. Hepcidin and regulation of body iron metabolism. American Journal of Physiology - Renal Physiology, 2006, 290, G199-G203.	3.4	269
236	Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. Journal of Clinical Investigation, 2006, 116, 1878-1885.	8.2	131
237	The suppression of hepcidin by anemia and erythropoietin (EPO) is mediated by a fall in serum iron. FASEB Journal, 2006, 20, LB84.	0.5	0
238	Hepcidin Suppression Following Phlebotomy Is Regulated by an Erythropoietic Regulator Found in Serum.. Blood, 2006, 108, 1554-1554.	1.4	0
239	Molecular and clinical correlates in iron overload associated with mutations in ferroportin. Haematologica, 2006, 91, 1092-5.	3.5	43
240	Hepcidin and iron-loading anemias. Haematologica, 2006, 91, 727-32.	3.5	95
241	Hepcidin is decreased in TFR2 hemochromatosis. Blood, 2005, 105, 1803-1806.	1.4	368
242	Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood, 2005, 106, 746-748.	1.4	170
243	A Portuguese patient homozygous for the -25C>A mutation of the HAMP promoter shows evidence of steady-state transcription but fails to up-regulate hepcidin levels by iron. Blood, 2005, 106, 2922-2923.	1.4	30
244	Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood, 2005, 106, 2196-2199.	1.4	274
245	Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood, 2005, 105, 1797-1802.	1.4	179
246	Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology, 2005, 42, 466-472.	7.3	54
247	Iron-regulatory protein hepcidin is increased in female athletes after a marathon. European Journal of Applied Physiology, 2005, 95, 569-571.	2.5	107
248	Differential Regulation of $\beta$ -Defensin Expression in Human Skin by Microbial Stimuli. Journal of Immunology, 2005, 174, 4870-4879.	0.8	225
249	Decreased clearance of <i>Pseudomonas aeruginosa</i> from airways of mice deficient in lysozyme M. Journal of Leukocyte Biology, 2005, 78, 1081-1085.	3.3	29
250	Defensins and Other Antimicrobial Peptides and Proteins. , 2005, , 95-110.		18
251	Distinct Defensin Profiles in <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> Urethritis Reveal Novel Epithelial Cell-Neutrophil Interactions. Infection and Immunity, 2005, 73, 4823-4833.	2.2	98
252	Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood, 2005, 106, 2884-2889.	1.4	239

#	ARTICLE	IF	CITATIONS
253	Hepcidin in iron overload disorders. <i>Blood</i> , 2005, 105, 4103-4105.	1.4	387
254	Reduced Paneth cell $\alpha$ -defensins in ileal Crohn's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18129-18134.	7.1	954
255	TGF- $\beta$ Regulates TLR Expression and Function on Epidermal Keratinocytes. <i>Journal of Immunology</i> , 2005, 174, 6137-6143.	0.8	146
256	Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 6843-6848.	7.1	487
257	The molecular basis of ferroportin-linked hemochromatosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8955-8960.	7.1	210
258	Defensins and Other Antimicrobial Peptides: A Historical Perspective and an Update. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2005, 8, 209-217.	1.1	108
259	Cellular iron: Ferroportin is the only way out. <i>Cell Metabolism</i> , 2005, 1, 155-157.	16.2	180
260	Human defensin gene copy number polymorphisms: Comprehensive analysis of independent variation in $\alpha$ - and $\beta$ -defensin regions at 8p22-23. <i>Genomics</i> , 2005, 86, 423-430.	2.9	181
261	Hepcidin is a regulator of intestinal iron absorption and iron recycling by macrophages. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 171-182.	1.7	325
262	Sensing Iron: Reciprocal Regulation of Hepcidin mRNA by Soluble and Cell-Associated Hemojuvelin.. <i>Blood</i> , 2005, 106, 512-512.	1.4	0
263	The N-Terminus of Hepcidin Is Essential for Its Interaction with Ferroportin: Structure-Function Study.. <i>Blood</i> , 2005, 106, 3588-3588.	1.4	0
264	Urinary Hepcidin in Thalassemic Syndromes.. <i>Blood</i> , 2005, 106, 3589-3589.	1.4	1
265	Ceruloplasmin Is Essential for the Mobilization of Tissue Iron Stores.. <i>Blood</i> , 2005, 106, 3581-3581.	1.4	0
266	Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. <i>Nature Genetics</i> , 2004, 36, 77-82.	21.4	900
267	Antimicrobial activity of innate immune molecules against <i>Streptococcus pneumoniae</i> , <i>Moraxella catarrhalis</i> and nontypeable <i>Haemophilus influenzae</i> . <i>BMC Infectious Diseases</i> , 2004, 4, 12.	2.9	125
268	Antimicrobial polypeptides. <i>Journal of Leukocyte Biology</i> , 2004, 75, 34-38.	3.3	167
269	Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. <i>Science</i> , 2004, 306, 2090-2093.	12.6	4,042
270	Lysozyme levels in the nasal secretions of patients with perennial allergic rhinitis and recurrent sinusitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 288-292.	1.0	40



#	ARTICLE	IF	CITATIONS
271	Defensins: antimicrobial peptides of vertebrates. <i>Comptes Rendus - Biologies</i> , 2004, 327, 539-549.	0.2	149
272	Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'UTR of the HAMP gene. <i>Blood</i> , 2004, 104, 2181-2183.	1.4	72
273	Increased Bronchoalveolar Lavage Human $\beta$ -Defensin Type 2 in Bronchiolitis Obliterans Syndrome after Lung Transplantation. <i>Transplantation</i> , 2004, 78, 1222-1224.	1.0	39
274	Hepcidin in iron metabolism. <i>Current Opinion in Hematology</i> , 2004, 11, 251-254.	2.5	144
275	Is Tfr2 the iron sensor?. <i>Blood</i> , 2004, 104, 3839-3840.	1.4	11
276	IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. <i>Journal of Clinical Investigation</i> , 2004, 113, 1271-1276.	8.2	1,809
277	IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. <i>Journal of Clinical Investigation</i> , 2004, 113, 1271-1276.	8.2	1,184
278	In Chronic Inflammation, There Exists an IL-6 Independent Pathway for the Induction of Hepcidin.. <i>Blood</i> , 2004, 104, 3205-3205.	1.4	13
279	Hepcidin Contributes to Anemia of Malignancy by Causing Sequestration of Iron in Hepatic Stores.. <i>Blood</i> , 2004, 104, 3197-3197.	1.4	0
280	In human epidermis, $\beta$ -defensin 2 is packaged in lamellar bodies. <i>Experimental and Molecular Pathology</i> , 2003, 74, 180-182.	2.1	447
281	Gut defence. <i>Nature</i> , 2003, 422, 478-479.	27.8	27
282	Angiogenin: an antimicrobial ribonuclease. <i>Nature Immunology</i> , 2003, 4, 213-214.	14.5	26
283	Defensins: antimicrobial peptides of innate immunity. <i>Nature Reviews Immunology</i> , 2003, 3, 710-720.	22.7	2,647
284	Antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. <i>FEBS Letters</i> , 2003, 535, 195-199.	2.8	7
285	Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. <i>Blood</i> , 2003, 102, 783-788.	1.4	1,306
286	The Role of Antimicrobial Peptides in Innate Immunity. <i>Integrative and Comparative Biology</i> , 2003, 43, 300-304.	2.0	240
287	Wound Healing and Expression of Antimicrobial Peptides/Polypeptides in Human Keratinocytes, a Consequence of Common Growth Factors. <i>Journal of Immunology</i> , 2003, 170, 5583-5589.	0.8	613
288	Expression of Antimicrobial Defensins in the Male Reproductive Tract of Rats, Mice, and Humans1. <i>Biology of Reproduction</i> , 2003, 68, 95-104.	2.7	202

#	ARTICLE	IF	CITATIONS
289	By IL-1 Signaling, Monocyte-Derived Cells Dramatically Enhance the Epidermal Antimicrobial Response to Lipopolysaccharide. <i>Journal of Immunology</i> , 2003, 170, 575-580.	0.8	157
290	Activation of Toll-Like Receptor 2 on Human Tracheobronchial Epithelial Cells Induces the Antimicrobial Peptide Human $\beta$ 2 Defensin-2. <i>Journal of Immunology</i> , 2003, 171, 6820-6826.	0.8	267
291	Increased inflammation in lysozyme M $\alpha$ deficient mice in response to <i>Micrococcus luteus</i> and its peptidoglycan. <i>Blood</i> , 2003, 101, 2388-2392.	1.4	95
292	Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. <i>Blood</i> , 2003, 101, 2461-2463.	1.4	1,245
293	Epithelia: Not just physical barriers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3357-3358.	7.1	82
294	Cationic Polypeptides Are Required for Antibacterial Activity of Human Airway Fluid. <i>Journal of Immunology</i> , 2002, 169, 6985-6991.	0.8	177
295	Versatile Defensins. <i>Science</i> , 2002, 298, 977-979.	12.6	62
296	The Solution Structure of Human Hepcidin, a Peptide Hormone with Antimicrobial Activity That Is Involved in Iron Uptake and Hereditary Hemochromatosis. <i>Journal of Biological Chemistry</i> , 2002, 277, 37597-37603.	3.4	339
297	Neutrophil defense in patients undergoing bone marrow transplantation: bactericidal/permeability-increasing protein (BPI) and defensins in graft-derived neutrophils1. <i>Transplantation</i> , 2002, 73, 1522-1526.	1.0	9
298	Cathelicidins: a family of endogenous antimicrobial peptides. <i>Current Opinion in Hematology</i> , 2002, 9, 18-22.	2.5	281
299	Overexpression and Structural Study of the Cathelicidin Motif of the Protegrin-3 Precursor. <i>Biochemistry</i> , 2002, 41, 21-30.	2.5	19
300	A Model for Antimicrobial Gene Therapy: Demonstration of Human $\beta$ 2-Defensin 2 Antimicrobial Activities In Vivo. <i>Human Gene Therapy</i> , 2002, 13, 2017-2025.	2.7	71
301	Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2002, 347, 1151-1160.	27.0	2,084
302	Antimicrobial factors in the cervical mucus plug. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 137-144.	1.3	205
303	Antimicrobial components of vaginal fluid. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 561-568.	1.3	217
304	Activation of a Src-dependent Raf $\alpha$ MEK1/2 $\alpha$ ERK signaling pathway is required for IL-1 $\alpha$ -induced upregulation of $\beta$ 2-defensin 2 in human middle ear epithelial cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002, 1590, 41-51.	4.1	80
305	Human $\beta$ 2-Defensin-2 Production in Keratinocytes is Regulated by Interleukin-1, Bacteria, and the State of Differentiation. <i>Journal of Investigative Dermatology</i> , 2002, 118, 275-281.	0.7	293
306	Defensins of vertebrate animals. <i>Current Opinion in Immunology</i> , 2002, 14, 96-102.	5.5	630

#	ARTICLE	IF	CITATIONS
307	Paneth cell trypsin is the processing enzyme for human defensin-5. <i>Nature Immunology</i> , 2002, 3, 583-590.	14.5	423
308	Antimicrobial polypeptides in host defense of the respiratory tract. <i>Journal of Clinical Investigation</i> , 2002, 109, 693-697.	8.2	159
309	Antimicrobial polypeptides in host defense of the respiratory tract. <i>Journal of Clinical Investigation</i> , 2002, 109, 693-697.	8.2	114
310	Using a Collaborative Weaning Plan to Decrease Duration of Mechanical Ventilation and Length of Stay in the Intensive Care Unit for Patients Receiving Long-Term Ventilation. <i>American Journal of Critical Care</i> , 2002, 11, 132-140.	1.6	39
311	The role of hepcidin in iron sequestration during infections and in the pathogenesis of anemia of chronic disease. <i>Israel Medical Association Journal</i> , 2002, 4, 1043-5.	0.1	42
312	Discovery of new human $\beta^2$ -defensins using a genomics-based approach. <i>Gene</i> , 2001, 263, 211-218.	2.2	241
313	Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. <i>FEBS Letters</i> , 2001, 504, 5-10.	2.8	80
314	Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. <i>Journal of Biological Chemistry</i> , 2001, 276, 7806-7810.	3.4	1,829
315	The NMR Structure of Human $\beta^2$ -Defensin-2 Reveals a Novel $\beta$ -Helical Segment,. <i>Biochemistry</i> , 2001, 40, 3810-3816.	2.5	134
316	Direct and indirect bacterial killing functions of neutrophil defensins in lung explants. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 281, L1240-L1247.	2.9	29
317	Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. <i>Blood</i> , 2001, 97, 297-304.	1.4	410
318	Expression, purification, crystallization and preliminary X-ray analysis of the cathelicidin motif of the protegrin-3 precursor. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2001, 57, 1677-1679.	2.5	8
319	Localized antimicrobial peptide expression in human gingiva. <i>Journal of Periodontal Research</i> , 2001, 36, 285-294.	2.7	227
320	Rings of destruction. <i>Nature</i> , 2001, 412, 392-393.	27.8	15
321	Detection of $\beta^2$ -defensins secreted by human oral epithelial cells. <i>Journal of Immunological Methods</i> , 2001, 256, 65-76.	1.4	102
322	An in vitro study of antibacterial properties of the cervical mucus plug in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 185, 586-592.	1.3	99
323	Cutting Edge: IFN-Inducible ELR <sup>+</sup> CXC Chemokines Display Defensin-Like Antimicrobial Activity. <i>Journal of Immunology</i> , 2001, 167, 623-627.	0.8	363
324	Determinants of <i>Staphylococcus aureus</i> Nasal Carriage. <i>Vaccine Journal</i> , 2001, 8, 1064-1069.	2.6	181

#	ARTICLE	IF	CITATIONS
325	Fatal Attraction Evaded. Journal of Experimental Medicine, 2001, 193, F31-F34.	8.5	35
326	Defensins in the Urinary Tract and Other Tissues. Journal of Infectious Diseases, 2001, 183, S41-S42.	4.0	52
327	Antimicrobial Activity of Leukocytes. , 2001, , 189-203.		2
328	Structural Study of the Pro-Sequence of Protegrin-3. , 2001, , 301-302.		0
329	Paneth cellsâ€”guardians of the gut cell hatchery. Nature Immunology, 2000, 1, 99-100.	14.5	67
330	Human Antimicrobial Peptides: Analysis and Application. BioTechniques, 2000, 29, 822-831.	1.8	56
331	Granulysin, a T Cell Product, Kills Bacteria by Altering Membrane Permeability. Journal of Immunology, 2000, 165, 7102-7108.	0.8	195
332	Regulation of Human Î²-Defensins by Gastric Epithelial Cells in Response to Infection with Helicobacter pylori or Stimulation with Interleukin-1. Infection and Immunity, 2000, 68, 5412-5415.	2.2	115
333	Microanalysis of antimicrobial properties of human fluids. Journal of Microbiological Methods, 2000, 41, 135-143.	1.6	20
334	Protegrins: new antibiotics of mammalian origin. Expert Opinion on Investigational Drugs, 2000, 9, 1731-1742.	4.1	84
335	Î²-Defensin Expression in Human Mammary Gland Epithelia. Pediatric Research, 2000, 48, 30-35.	2.3	60
336	Impaired Innate Immunity in the Newborn: Newborn Neutrophils Are Deficient in Bactericidal/Permeability-Increasing Protein. Pediatrics, 1999, 104, 1327-1333.	2.1	190
337	Antimicrobial peptides in mammalian and insect host defence. Current Opinion in Immunology, 1999, 11, 23-27.	5.5	935
338	Antibiotic peptides from higher eukaryotes: biology and applications. Trends in Molecular Medicine, 1999, 5, 292-297.	2.6	177
339	Defensins and Host Defense. Science, 1999, 286, 420-421.	12.6	323
340	A 450-kb contig of defensin genes on human chromosome 8p23. Gene, 1999, 233, 205-211.	2.2	92
341	Oxygenâ€”Independent Microbicidal Mechanisms of Phagocytes. Proceedings of the Association of American Physicians, 1999, 111, 390-395.	2.0	23
342	Porcine Epithelial Î²-Defensin 1 Is Expressed in the Dorsal Tongue at Antimicrobial Concentrations. Infection and Immunity, 1999, 67, 3121-3127.	2.2	97

#	ARTICLE	IF	CITATIONS
343	Innate Antimicrobial Activity of Nasal Secretions. Infection and Immunity, 1999, 67, 3267-3275.	2.2	251
344	Antimicrobial peptides of vertebrates. Current Opinion in Immunology, 1998, 10, 41-44.	5.5	353
345	Structure and mapping of the human $\alpha$ 2-defensin HBD-2 gene and its expression at sites of inflammation. Gene, 1998, 222, 237-244.	2.2	246
346	An Antimicrobial Activity of Cytolytic T Cells Mediated by Granulysin. Science, 1998, 282, 121-125.	12.6	906
347	Molecular cloning and tissue expression of porcine $\alpha$ 2-defensin-1. FEBS Letters, 1998, 424, 37-40.	2.8	78
348	Isolation of human intestinal defensins from ileal neobladder urine. FEBS Letters, 1998, 434, 272-276.	2.8	70
349	Production of $\alpha$ 2-defensins by human airway epithelia. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14961-14966.	7.1	554
350	The Role of Protegrins and Other Elastase-Activated Polypeptides in the Bactericidal Properties of Porcine Inflammatory Fluids. Infection and Immunity, 1998, 66, 3611-3617.	2.2	65
351	Antimicrobial peptides of leukocytes. Current Opinion in Hematology, 1997, 4, 53-58.	2.5	157
352	Differential Scanning Microcalorimetry Indicates That Human Defensin, HNP-2, Interacts Specifically with Biomembrane Mimetic Systems,. Biochemistry, 1997, 36, 1525-1531.	2.5	103
353	Laboratory Production of Antimicrobial Peptides in Native Conformation. , 1997, 78, 115-132.		29
354	The Human $\alpha$ 2-Defensin-1 and $\alpha$ 1-Defensins Are Encoded by Adjacent Genes: Two Peptide Families with Differing Disulfide Topology Share a Common Ancestry. Genomics, 1997, 43, 316-320.	2.9	221
355	Defensin Stimulates the Binding of Lipoprotein (a) to Human Vascular Endothelial and Smooth Muscle Cells. Blood, 1997, 89, 4290-4298.	1.4	72
356	Purification and characterization of defensins from cystic fibrosis sputum. Inflammation Research, 1997, 46, 98-102.	4.0	117
357	Endogenous Vertebrate Antibiotics.. Annals of the New York Academy of Sciences, 1996, 797, 228-239.	3.8	130
358	Defensin Modulates Tissue-type Plasminogen Activator and Plasminogen Binding to Fibrin and Endothelial Cells. Journal of Biological Chemistry, 1996, 271, 17650-17655.	3.4	72
359	Defensins and other endogenous peptide antibiotics of vertebrates. Journal of Leukocyte Biology, 1995, 58, 128-136.	3.3	298
360	Defensins. , 1995, 66, 191-205.		297

#	ARTICLE	IF	CITATIONS
361	The structure of porcine protegrin genes. FEBS Letters, 1995, 368, 197-202.	2.8	85
362	Structures of genes for two cathelin-associated antimicrobial peptides: prophenin-2 and PR-39. FEBS Letters, 1995, 376, 130-134.	2.8	70
363	Murine 32D cl3 cells – A transfectable model of phagocyte granule formation. Journal of Immunological Methods, 1995, 181, 253-258.	1.4	14
364	Defensins. Current Opinion in Immunology, 1994, 6, 584-589.	5.5	376
365	Defensins: a family of antimicrobial and cytotoxic peptides. Toxicology, 1994, 87, 131-149.	4.2	190
366	Identification of defensin binding to C1 complement. FEBS Letters, 1994, 356, 169-173.	2.8	57
367	Neutrophil defensins: Purification, characterization, and antimicrobial testing. Methods in Enzymology, 1994, 236, 160-172.	1.0	122
368	Biosynthesis of Defensins and Other Antimicrobial Peptides. Novartis Foundation Symposium, 1994, 186, 62-76.	1.1	31
369	The structure of neutrophil defensin genes. FEBS Letters, 1993, 321, 267-273.	2.8	61
370	The effect of biotinylation on the antigenic specificity of anti-defensin monoclonal antibodies. Journal of Immunological Methods, 1993, 158, 237-242.	1.4	10
371	Defensins Reduce the Barrier Integrity of a Cultured Epithelial Monolayer without Cytotoxicity. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 193-200.	2.9	34
372	Cationic defensins arise from charge-neutralized propeptides: a mechanism for avoiding leukocyte autocytotoxicity?. Journal of Leukocyte Biology, 1992, 51, 634-639.	3.3	123
373	Defensins: microbicidal and cytotoxic peptides of mammalian host defense cells. Medical Microbiology and Immunology, 1992, 181, 99-105.	4.8	29
374	Defensins: Endogenous antibiotic peptides of animal cells. Cell, 1991, 64, 229-230.	28.9	365
375	An enzyme immunoassay for human defensins. Journal of Immunological Methods, 1991, 141, 149-155.	1.4	63
376	Activated $\alpha_2$ -Macroglobulin Is a Principal Defensin-binding Protein. American Journal of Respiratory Cell and Molecular Biology, 1991, 5, 101-106.	2.9	107
377	Killing of oral, gram-negative, facultative bacteria by the rabbit defensin, NP-1. Oral Microbiology and Immunology, 1990, 5, 315-319.	2.8	25
378	Direct Cytotoxicity of Polymorphonuclear Leukocyte Granule Proteins to Human Lung-derived Cells and Endothelial Cells. The American Review of Respiratory Disease, 1990, 141, 179-185.	2.9	154

#	ARTICLE	IF	CITATIONS
379	A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. <i>Journal of Allergy and Clinical Immunology</i> , 1990, 86, 202-210.	2.9	505
380	Defensins. <i>European Journal of Haematology</i> , 1990, 44, 1-8.	2.2	282
381	The opsonizing ligand on <i>Salmonella typhimurium</i> influences incorporation of specific, but not azurophil, granule constituents into neutrophil phagosomes.. <i>Journal of Cell Biology</i> , 1989, 109, 2771-2782.	5.2	108
382	Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in <i>E. coli</i> by multiple-wavelength spectrophotometry. <i>Journal of Immunological Methods</i> , 1988, 108, 153-158.	1.4	210
383	Synergistic cytotoxicity mediated by hydrogen peroxide combined with peptide defensins. <i>Cellular Immunology</i> , 1988, 114, 104-116.	3.0	63
384	Defensins. <i>Clinical Immunology Newsletter</i> , 1987, 8, 134-137.	0.1	0
385	In Vitro Killing of Spores and Hyphae of <i>Aspergillus fumigatus</i> and <i>Rhizopus oryzae</i> by Rabbit Neutrophil Cationic Peptides and Bronchoalveolar Macrophages. <i>Journal of Infectious Diseases</i> , 1986, 154, 483-489.	4.0	193
386	Molecular Cloning of the Rat Metallothionein 1 (MT-1) mRNA Sequence. <i>DNA and Cell Biology</i> , 1983, 2, 15-22.	5.2	79
387	Stripline coupling to Josephson oscillators. <i>Journal of Applied Physics</i> , 1975, 46, 4986-4988.	2.5	10
388	Defensins and Other Antimicrobial Peptides: Innate Defense of Mucosal Surfaces. , 0, , 17-34.		10
389	Title is missing!. , 0, 1, .		0
390	Defensins and Cathelicidins: Antimicrobial Peptide Effectors of Mammalian Innate Immunity. , 0, , 105-110.		0
391	Antimicrobial Proteins. , 0, , 345-356.		0
392	The Molecular Basis of Iron Metabolism. , 0, , 169-178.		0
393	Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. <i>American Journal of Hematology</i> , 0, , .	4.1	6